Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists

Brain Research

Volumn 821, Issue 2, 1999, Pages 539-545

  Johnson, Michael P ^a   Chamberlain, Maryjo ^a   Kelly, Gerard M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

CHPG; DHPG; Group I; In vivo; Metabotropic glutamate; Phosphatidyl inositol hydrolysis

Indexed keywords

1 AMINO 1,3 CYCLOPENTANEDICARBOXYLIC ACID; 2 AMINO 2 (2 CARBOXYPROPAN 1 YL) 3 (DIBENZOPYRAN 4 YL)PROPANOIC ACID; 2 AMINO 4 PHOSPHONOBUTYRIC ACID; 3,5 DIHYDROXYPHENYLGLYCINE; EGLUMETAD; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; INOSITOL PHOSPHATE; LITHIUM CHLORIDE; PHOSPHATIDYLINOSITIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVATION; FRONTAL CORTEX; HIPPOCAMPUS; HYDROLYSIS; IN VIVO STUDY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; ION EXCHANGE CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY;

AMINO ACIDS; ANIMALS; BRAIN CHEMISTRY; CEREBELLUM; CYCLOLEUCINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; HIPPOCAMPUS; HYDROLYSIS; INJECTIONS, INTRAVENTRICULAR; MALE; NEUROPROTECTIVE AGENTS; PHENYLACETATES; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASE C; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RESORCINOLS; TRITIUM; XANTHENES;

EID: 0033550927     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01065-3     Document Type: Article

References (26)

1. Allison J.H., Blisner M.E., Holland W.H., Hipps P.P., Sherman W.R. Increased brain myo-inositol 1-phosphate in lithium-treated rats. Biochem. Biophys. Res. Commun. 71:1976;664-670.
2. Allison J.H., Stewart M.A. Reduced brain inositol in lithium-treated rats. Nature - New Biology. 233:1971;267-268.
3. Battaglia G., Monn J.A., Schoepp D.D. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats. Neurosci. Lett. 229:1997;161-164.
4. Bymaster F.P., Carter P.A., Peters S.C., Zhang W., Ward J.S., Mitch C.H., Calligaro D.O., Whitesitt C.A., DeLapp N., Shannon H.E., Rimvall K., Jeppesen L., Sheardown M.J., Fink-Jensen A., Sauerberg P. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 795:1998;179-190.
5. Doherty A.J., Palmer M.J., Henley J.M., Collingridge G.L., Jane D.E. (RS)-2-Chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology. 36:1997;265-267.
6. Hallcher L.M., Sherman W.R. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255:1980;10896-10901.
7. Ito I., Kohda A., Tanabe S., Hirose E., Hayashi M., Mitsunaga S., Sugiyama H. 3,5-Dihydroxyphenylglycine: a potent agonist of metabotropic glutamate receptors. Neuroreport. 3:1992;1013-1016.
8. Kingston A.E., Ornstein P.L., Wright R.A., Johnson N.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., Schoepp D.D. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 37:1998;1-12.
9. Klein J., Reymann K.G., Riedel G. Activation of phospholipases C and D by the novel metabotropic glutamate receptor agonist tADA. Neuropharmacology. 36:1997;261-263.
10. Margolis R.U., Heller A. The effect of cholinergic and other pharmacologic agents on brain monophosphoinositide turnover in vivo. J. Pharmacol. Exp. Ther. 151:1966;307-312.
11. Meldrum B., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11:1990;379-387.
12. Monaghan D.T., Bridges R.J., Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 29:1989;365-402.
13. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J. Med. Chem. 40:1997;528-537.
14. Ozawa S., Kamiya H., Tsuzuski K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54:1998;581-618.
15. Patel S., Freedman B. The muscarinic receptor agonist L-658,903 modulates the in vivo accumulation of inositol monophosphates in mouse brain. Eur. J. Pharmacol. 267:1994;329-334.
16. Schoepp D.D. Manganese stimulates the incorporation of [3H]inositol into a pool of phosphatidylinositol in brain that is not coupled to agonist-induced hydrolysis. J. Neurochem. 45:1985;1481-1486.
17. Schoepp D.D. Novel functions for subtypes of metabotropic glutamate receptors. Neurochem. Int. 24:1994;439-449.
18. Schoepp D.D., Goldworthy B.G., Johnson B.G., Salhoff C.R., Baker R. 3,5-Dihydroxyphenylglycine is a highly selective agonist for phosphonoinostide-linked metabotropic glutamate receptors in the rat hippocampus. J. Neurochem. 63:1994;769-772.
19. Schoepp D.D., Johnson B.G., Wright R.A., Salhoff C.R., Mayne N.G., Wu N.S., Cockerham S.L., Burnett J.P., Belagaje R., Bleakman D., Monn J.A. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology. 36:1997;1-11.
20. Schoepp D.D., Sacann A.I. Metabotropic glutamate receptors and neuronal degenerative disorders. Neurobio. Aging. 15:1994;261-263.
21. Sherman W.R., Munsell L.Y., Gish B.G., Honchar M.P. Effects of systemically administered lithium on phosphoinositide metabolism in rat brain, kidney, and testis. J. Neurochem. 44:1985;798-807.
22. Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J. Comp. Neurol. 322:1992;121-135.
23. Shigemoto R., Nomura S., Ohishi H., Sugihara H., Nakanishi S., Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163:1993;53-57.
24. Tizzano J.P., Griffey K.I., Schoepp D.D. Induction or protection of limbic seizures in mice by mGluR subtype selective agonists. Neuropharmacology. 34:1995;1063-1067.
25. Whitworth P., Heal D.J., Kendall D.A. The effects of acute and chronic lithium treatment on pilocarpine-stimulated phosphoinositide hydrolysis in mouse brain in vivo. Br. J. Pharmacol. 101:1990;39-44.
26. W. Zhang, F.P. Bymaster, The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors, Psychopharmacology (in press).